Histone deacetylase 2 inhibitor valproic acid attenuates bisphenol A-induced liver pathology in male mice.

Accumulating evidence indicates the role of endocrine disruptor bisphenol A (BPA) in many pathological conditions. Histone deacetylase (HDAC) inhibition has potential for the treatment of many diseases/abnormalities. Using a mouse BPA exposure model, this study investigated the hepatoprotective effects of the Food and Drug Administration-approved HDAC2 inhibitor valproic acid (VPA) against BPA-induced liver pathology.